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Abstract
Background: Monocarboxylate transporters (MCTs) are transmembrane proteins involved in the transport of
monocarboxylates across the plasma membrane, which appear to play an important role in solid tumours,
however the role of MCTs in prostate cancer is largely unknown. The aim of the present work was to evaluate the
clinico-pathological value of monocarboxylate transporters (MCTs) expression, namely MCT1, MCT2 and MCT4,
together with CD147 and gp70 as MCT1/4 and MCT2 chaperones, respectively, in prostate carcinoma.
Methods: Prostate tissues were obtained from 171 patients, who performed radical prostatectomy and 14 patients
who performed cystoprostatectomy. Samples and clinico-pathological data were retrieved and organized into
tissue microarray (TMAs) blocks. Protein expression was evaluated by immunohistochemistry in neoplastic (n =
171), adjacent non-neoplastic tissues (n = 135), PIN lesions (n = 40) and normal prostatic tissue (n = 14). Protein
expression was correlated with patients’ clinicopathologic characteristics.
Results: In the present study, a significant increase of MCT2 and MCT4 expression in the cytoplasm of tumour cells
and a significant decrease in both MCT1 and CD147 expression in prostate tumour cells was observed when
compared to normal tissue. All MCT isoforms and CD147 were expressed in PIN lesions. Importantly, for MCT2 and
MCT4 the expression levels in PIN lesions were between normal and tumour tissue, which might indicate a role for
these MCTs in the malignant transformation. Associations were found between MCT1, MCT4 and CD147
expressions and poor prognosis markers; importantly MCT4 and CD147 overexpression correlated with higher PSA
levels, Gleason score and pT stage, as well as with perineural invasion and biochemical recurrence.
Conclusions: Our data provides novel evidence for the involvement of MCTs in prostate cancer. According to our
results, we consider that MCT2 should be further explored as tumour marker and both MCT4 and CD147 as
markers of poor prognosis in prostate cancer.
Background
Increased glucose consumption is a hallmark of malig-
nant cells, which is responsible for energy production
from glycolysis [1]. Most malignancies rely on this path-
way for rapid proliferation even in the presence of oxy-
gen, leading to production of large amounts of acids,
mainly lactic acid [1,2]. Consequently, the high glycoly-
tic phenotype induces an acidic tumour environment,
which is associated with the increase of several malig-
nant features including cellular migration, invasion and
metastisation [2].
In order to prevent cell death by cellular acidosis,
tumour cells increase proton efflux through pH regula-
tors such as proton-pumps, sodium-proton exchangers,
bicarbonate transporters and monocarboxylate transpor-
ters (MCTs) [3]. MCTs are proteins that facilitate the
transmembrane transport of short-chain fatty acids,
such as pyruvate and lactate, coupled with a proton. In
glycolytic tumours, they promote the efflux of lactic
acid, constituting important players in the maintenance
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of tumour intracellular pH, as well as in the mainte-
nance of the high rates of glycolysis [4,5]. Therefore,
MCTs play a central role in tumour metabolism and, as
a result, constitute attractive targets in cancer therapy
which have not been explored yet.
We and others have shown evidence for the upregula-
tion of MCTs in several solid tumours, such as colorectal
carcinomas [6], uterine cervix carcinomas [7], melanomas
[8], breast carcinomas [9,10] and lung tumours [11].
However, in prostate carcinoma, the role of MCTs is lar-
gely unknown. To the best of our knowledge, we were
the first to report MCT expression in prostate cancer
[12,13], however, there is a recent study [14] evaluating
the role of MCTs in prostate drug resistance and pro-
gression but this study does not evaluate neither MCT
isoform 2 (MCT2) nor gp70, its known chaperone.
MCT expression appears to be influenced by altered
physiologic conditions, however the underlying molecu-
lar events involved in MCT regulation are still poorly
understood. Recently, it was demonstrated that proper
expression and activity of MCT1 and MCT4 requires
co-expression of CD147, also known as EMMPRIN or
basigin [15-17]. On the other hand, in vitro studies
showed that maturation and cell surface expression of
CD147 is also dependent on MCT1 and MCT4 expres-
sions [18,19]. MCT2 expression and activity depends on
a different chaperone known as gp70.
CD147 alone has already been described as a key ele-
ment in oncogenesis by stimulating the synthesis of sev-
eral matrix metalloproteinases, leading to enhanced
tumour cell invasion [20,21]. This protein is described to
be up-regulated in tumours, including prostate cancer,
where it has been identified as an unfavourable prognosis
marker [22-25]. However, the role of CD147/MCT co-
expression in prostate cancer is far from understood.
The aim of the present study was to assess the role of
MCTs in prostate cancer, by comparing the immunohis-
tochemical expression of the MCT isoforms 1, 2 and 4,
along with CD147 and gp70, in normal prostatic tissue,
adjacent non-neoplastic tissue, PIN lesions and neoplas-
tic tissues in a large series of prostate samples organized
into tissue microarrays (TMAs), and evaluating their
clinico-pathological value.
Methods
Case selection and TMA construction
Prostate tissues were obtained from 171 patients with a
median age of 64 years old (range 46-74), who per-
formed radical prostatectomy between 1993 and 2003.
Samples and clinico-pathological data were retrieved
from the files of the Department of Pathology, Centro
Hospitalar do Porto and Centro Hospitalar do Alto Ave-
Guimarães, and organized into 13 tissue microarray
blocks (TMAs).
Prior to TMA construction, hematoxylin and eosin
(H&E) tumour sections of each specimen of radical
prostatectomy were re-assessed using the 2005 modified
Gleason and 2010 p TNM AJCC classification [26,27].
Representative areas of adjacent non-neoplastic prostate
tissue, PIN lesions and prostate cancer were selected.
Adjacent non-neoplastic tissue samples and PIN lesions
were selected from the peripheral zone of prostate were
cancer develops. Each case was represented in the TMA
by three cores (1 mm diameter) with 0.8 mm from core
centre to core centre, and precisely deposited into a
recipient paraffin block, using a TMA workstation
(TMA builder, Beecher Instruments Inc. Technology). 4
μm tissue sections were used for immunohistochemistry
(IHC) and H&E-stained section from each TMA block
was reviewed to confirm the presence of morphological
representative areas of the original tissues.
Normal prostate tissue was obtained from cystoprosta-
tectomy cases and immunohistochemical expression was
performed in the entire section of the fragments.
MCT and CD147 immunohistochemistry
IHC for MCTs was performed according to avidin-bio-
tin-peroxidase complex principle (R.T.U. Vectastain
Elite ABC Kit [Universal], Vector Laboratories, Burlin-
game, CA), with the primary antibodies for MCT1
(AB3538P, Chemicon International, Temecula, CA),
MCT2 (sc-14926, Santa Cruz Biotechnology, Santa
Cruz, CA) and MCT4 (AB3316P, Chemicon Interna-
tional, Temecula, CA), diluted 1:200, as previously
described [6,7,9,10].
CD147 and gp70 IHC was performed according to the
same principle (Ultravision Detection System Antipoly-
valent, horseradish peroxidase; Lab Vision Corporation),
with the primary antibody diluted 1:750, as previously
described [9,10] for CD147 (18-7344, ZYMED Labora-
tories Inc., South San Francisco, CA) and diluted 1:100
for gp70 (HPA017740, Atlas Antibodies).
Negative controls were performed with appropriate
serum controls for the primary antibodies (X0907 and
N1699, Dako, Carpinteria, CA). Normal colon, kidney
and skeletal muscle tissue were used as positive con-
trols for MCT1, MCT2 and MCT4, respectively, cervi-
cal squamous carcinoma for CD147 and seminal
vesicle for gp70. Tissue sections were counterstained
with hematoxylin.
Immunohistochemical evaluation
Immunoreaction in TMA sections was evaluated for
cytoplasmic and/or plasma membrane staining. Shortly,
sections were scored semi-quantitatively as follows: 0:
0% of immunoreactive cells; 1: < 5% of immunoreactive
cells; 2: 5-50% of immunoreactive cells and 3: > 50% of
immunoreactive cells. Also, intensity of staining was
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scored semi-quantitatively as follows: 0: negative; 1: weak;
2: moderate and 3: strong. The final score was defined as
the sum of both parameters (extension and intensity), and
grouped as negative (scores 0-3) and positive (scores 4-6).
Discordant results in different cores of the same case were
scored as follows: average of extension plus highest inten-
sity score. Immunohistochemical evaluation was per-
formed by two independent and experienced pathologists
(JRV, PM), who were blind to the clinico-pathological data
of the patients. Discordant results were discussed in a dou-
ble-head microscope. Since staining was different among
the positive cases, to further clarify the significance of the
immunoexpression of MCTs and CD147 in prostate carci-
noma, we categorized the cases in two groups: intermedi-
ate score group (ISG, score 4) and high score group (HSG,
scores 5-6).
Statistics
Statistical analysis was performed using the SPSS statis-
tical software (version 17.0, SPSS Inc., Chicago, IL,
USA). All comparisons were examined for statistical sig-
nificance using Pearson’s chisquare (c2) test, being the
threshold for significance p < 0.05.
Ethics
The work has been approved by DEFI (Departamento de
Ensino Formação e Investigação) Ethics Committee of
Centro Hospitalar do Porto ref. no. 017/08(010-DEFI/
015-CES).
Results
MCT, CD147 and gp70 expressions in prostate tissues
A total of 346 prostate samples organised into TMAs (tis-
sue microarrays), including 135 non-neoplastic, 40 PIN
lesions and 171 neoplastic tissues were analysed for
MCT1, MCT2, MCT4, CD147 and gp70 expressions.
Also, 14 normal prostate tissues were analysed for MCTs,
CD147 and gp70 expressions. We used a combined scor-
ing system, previously described [6,7,9,10]. To better illus-
trate the scoring system used, representative images of
positive cases with intensity score 1 (weak), score 2 (mod-
erate) and score 3 (strong), for MCT1, MCT2, MCT4 and
CD147 staining are shown in Figure 1.
Figure 2 summarises MCT and CD147 expressions in
normal, adjacent non-neoplastic, PIN lesions and
tumour tissues. A significant increase in both MCT2
and MCT4 expressions was observed from non-neoplas-
tic (normal or adjacent) to tumour tissues (p < 0.001,
for both) while a decrease was observed for MCT1
expression in the transition from normal or adjacent
non-neoplastic to prostate tumour tissue (p = 0.003 and
p < 0.001, respectively). CD147 expression decreased
from normal to tumour tissue (p = 0.006), however, no
significant differences were observed when compared to
adjacent non-neoplastic tissue (p = 0.236). For MCT1
expression, we observed a decrease from PIN lesions to
malignant glands (p < 0.001) with no significant differ-
ences between normal or adjacent non-neoplastic tissue
and PIN lesions (p = 0.545 and p = 0.063, respectively).
For MCT2, there was an increase from both normal and
adjacent non-neoplastic tissue to PIN lesions (p < 0.001
and p = 0.005, respectively) whereas no significant dif-
ferences were observed between PIN lesions and tumour
(p = 0.605). There was a significant increase in MCT4
expression from normal to PIN lesions (p = 0.024) and
from PIN lesions to tumour (p = 0.022) but not between
adjacent non-neoplastic tissue and PIN lesions (p =
0.410). For CD147, there was a significant decrease from
normal tissue to PIN lesions (p = 0.043) but no differ-
ence between adjacent non-neoplastic tissue and PIN
lesions (p = 0.389). No differences were observed
between CD147 expression in PIN lesions and tumour
(p = 0.180). Gp70 was negative in all normal, adjacent
non-neoplastic and PIN lesions and only a very small
percentage of cases (n = 4) were positive in tumours
(data not shown).
Figure 3 shows representative immunohistochemical
reactions for MCT1, MCT2, MCT4 and CD147 in nor-
mal, PIN lesions and tumour tissue. Staining for MCT1
and CD147 was mainly observed in the basal and lateral
epithelial cell membranes, with negative immunoreac-
tions in the apical zone of both normal glands (Figure
3A, J) PIN lesions (Figure 3B, K) and neoplastic cells
(Figure 3C, L). MCT2 and MCT4 staining was cytoplas-
mic, with granular appearance, which was more evident
for MCT2 (Figure 1F). Due to the epithelial nature of
prostate carcinoma, positive immunoreactions were only
considered for staining in epithelial cells.
As stated in Materials and Methods section, we stratified
the positive cases into two groups, ISG (intermediate score
group) and HSG (high score group). Although the number
of normal prostate tissue cases is small, the differences
between normal and tumour cases was evident, however,
this difference was not so clear between adjacent non-neo-
plastic tissue and tumour. Thus, we compared the expres-
sion of the proteins in the ISG and HSG (Table 1). For
both MCT1 and MCT4, there was a significant difference
between neoplastic and adjacent non-neoplastic tissues
only for the HSG. For MCT2, HSG predominated in neo-
plastic cells, whereas ISG was more frequent in adjacent
non-neoplastic tissue. There were no differences in the
distribution of CD147 final score between neoplastic and
adjacent non neoplastic tissues.
We further assessed the association between CD147
and MCT expressions in the prostate cancer tissues
(Table 2). This analysis showed that CD147 correlated
with both MCT1 and MCT4 (p < 0.001 for both), but
not with MCT2. Figure 3 (C, I and L) shows staining for
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MCT1, MCT4 and CD147 in the same tumour area of
one prostate tumour case, in which positive cells for the
three proteins can be seen. No associations between
gp70 and MCTs were found (data not shown).
Associations between MCTs and CD147 expressions and
the clinic-pathological data
Assessment of association between MCTs and CD147
expressions and the clinico-pathological data is
presented in Table 3. We found positive associations
between MCT1 expression in the HSG and higher PSA
levels (p = 0.016), absence of perineural invasion (p =
0.036) and presence of biochemical recurrence (p =
0.047). For MCT2, there was only an association with
lower age at diagnosis for ISG (p = 0.023). MCT4
expression in the HSG was associated with higher age
Figure 1 Expression of MCT1, MCT2, MCT4 and CD147 in prostate cancer tissue microarrays. Representative images of intensity score 1
(weak) for MCT1 (A), MCT2 (D), MCT4 (G) and CD147 (J), intensity score 2 (moderate) for MCT1 (B), MCT2 (E), MCT4 (H) and CD147 (K) and
intensity score 3 (strong) for MCT1 (C), MCT2 (F), MCT4 (I) and CD147 (L) immunostaining for positive cases of prostate carcinoma (score ≥ 4).
Figure 2 Frequency of MCTs and CD147 expressions in normal
prostate, non-neoplastic, PIN lesions and tumour samples. In
general, there is an increase in both MCT2 and MCT4 expressions
from non-neoplastic (normal or adjacent) to tumour tissues, while a
decrease is observed for MCT1 and CD147 expression in the
transition from non-neoplastic (normal or adjacent) to prostate
tumour tissue. See text for detail. * p < 0.05 (non-neoplastic
adjacent, PIN and tumour tissue compared to normal tissue).
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(p < 0.001), higher PSA levels (p < 0.001), advanced
tumour stage (pT3, p < 0.001), higher Gleason score
(p = 0.011), presence of perineural invasion (p = 0.011)
and presence of biochemical recurrence (p < 0.001).
CD147 expression in the HSG correlated with higher
age (p < 0.001), higher PSA levels (p<0.001), advanced
tumour stage (pT3, p < 0.001), higher Gleason score
(p = 0.012), presence of perineural invasion (p = 0.021)
and presence of biochemical recurrence (p < 0.001). No
associations between gp70 and clinico-pathological data
were found (data not shown).
Discussion
Prostate cancer remains a major concern in public
health, being one of the most prevalent tumours and
the second leading cause of cancer death in men [28].
Thus, it is important to elucidate its biology in order to
find new markers and more efficient treatments.
Experimental evidence points at MCTs as potential
targets for cancer therapy [29,30], however, the role of
these membrane proteins in prostate cancer is poorly
understood. Thus, the present work is an attempt to
shed light into the involvement of MCTs in prostate
Figure 3 Immunohistochemical expression of MCTs and CD147 in normal, PIN lesions and neoplastic prostate tissue . MCT1
immunoreactivity in normal glands (A), PIN lesions (B) and malignant glands (C) was observed in the basal and lateral epithelial cell membranes
(solid arrow head) with no immunoreaction in the apical zone (open arrow head). MCT2 immunoreactivity in normal (D), PIN lesions (E),
malignant glands (F) was mainly observed in the cytoplasm of epithelial cells, being absent in the normal glands (solid arrow head) but with
strong granular pattern in malignant glands and PIN lesion (open arrow head). MCT4 immunoreactivity in normal glands (G), PIN lesions (H)
malignant glands (I) was observed in the cytoplasm, with granular appearance (open arrow head), being absent in normal glands (solid arrow
head). CD147 immunoreactivity in normal glands (J), PIN lesions (K) and malignant glands (L) was observed in the basal and lateral epithelial cell
membranes (solid arrow head), with no immunoreaction in the apical zone (open arrow head). Main pictures are at 200× magnification and
insets are at 400×.
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cancer. With this purpose, we analysed the expressions
of MCT1, MCT2, MCT4, CD147 and gp70 in a series of
prostate samples, including normal, adjacent non-neo-
plastic, PIN lesions and neoplastic tissues.
MCT1, MCT2, MCT4 and CD147 are differentially
expressed in non-neoplastic, PIN lesions and neoplastic
prostate tissues
In the present study, a general decrease in MCT1 and
CD147 levels from normal prostate tissue to PIN lesions
and prostate carcinoma was observed. Since their
expression in normal prostate epithelium is high, it
appears that they have an important role in normal tis-
sue and are downregulated in prostate cancer cells,
where other adaptive mechanisms may be activated.
Importantly, there was an increase in both MCT2 and
MCT4 expressions from normal to PIN lesions and
tumour samples. In part, our results contradict the ones
of Hao et al. [14], which stated that both MCT1 and
MCT4 are upregulated in prostate cancer tissue, how-
ever the percentage of MCT4 positivity for pT3 tumours
(around 40%) is similar to ours (44% tumour positive
cases). Since the number of cases analysed by these
authors is only slightly smaller than ours, the differences
observed may be due to the different antibodies used.
The specificity of our antibodies was tested by western-
blot and more recently by RNAi for MCT1 (data not
shown). We also observed frequent and clear MCT1
membrane expression, while these authors state that
MCT1 staining was mostly cytoplasmic. The granular
appearance of MCT2 and MCT4 expression in the cyto-
plasm of prostate tumour cells, as well as the predomi-
nance of the strong immunostaining scores suggests
that these MCT isoforms could have important func-
tions in some organelle membranes, possibly playing a
role in the metabolism of prostate tumour cells.
Importantly, MCT2 was the only marker which
allowed distinction between adjacent non-neoplastic tis-
sue and PIN lesions. For MCT1, MCT4 and CD147,
expression was similar in both. Despite apparently nor-
mal to the Pathologist, adjacent non-neoplastic glands
already present alterations from normal tissue.
Monocarboxylate transporters 1 and 4 expression is
associated with CD147 in prostate cancer
A close association between CD147 expression and both
MCT1 and 4 was found, similar to the findings of Hao
et al. [14]. Additionally, we detected no association with
MCT2, supporting CD147 as chaperone for both MCT1
and MCT4 but not with MCT2 in prostate cancer. Stu-
dies of CD147 in paraffin-embedded specimens of pros-
tate cancer are not many, however they describe
overexpression of CD147 in prostate cancer, reporting
expressions between 60 to 80% [22-25]. In the present
study, we found around 50% of prostate tumour cases
expressing CD147 and this expression was significantly
different from the normal prostate tissue. To the best of
our knowledge, our study has the biggest sample size
and the number of non-neoplastic samples analysed is
similar to the tumour samples.
Gp70 was only expressed in very few cancer cases and
there was no association with either MCT isoforms.
This result was surprising, however, since MCT2 was
not present in the plasma membrane, the mechanism of
regulation might be different. In addition, as described
for CD147 and MCT isoforms 1 and 4 [31], there might
be other chaperones involved in MCT2 regulation.
MCT4 and CD147 overexpression is associated with poor
prognosis in prostate cancer
Assessment of associations between MCTs and CD147
expression and clinico-pathological data, revealed some
Table 1 Distribution of positive final
immunohistochemical score of monocarboxylate
transporters (MCTs) and CD147 in adjacent non-tumoural
(NT) and tumour tissue (T) of prostate samples
ISG (%) HSG (%)
n (Score 4) p (Scores 5-6) p
MCT1 0.500 0.002
NT 121 17.4 66.9
T 166 18.0 46.4
MCT2 0.048 < 0.001
NT 132 37.9 16.7
T 166 26.0 53.0
MCT4 0.474 < 0.001
NT 128 16.4 7.8
T 168 20.8 23.2
CD147 0.211 0.153
NT 134 11.9 41.1
T 167 16.7 32.9
ISG, intermediate score group; HSG, high score group.
Table 2 Association between MCT1, MCT2, MCT4 and CD147 expressions in prostate tumours
MCT1 MCT4 MCT2
n Positive (%) p n Positive (%) p n Positive (%) p
CD147 < 0.001 < 0.001 0.184
Negative 59 20.3 84 26.7 35 40.0
Positive 107 64.5 83 63.0 131 50.4
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important associations. In accordance to the work of
other groups, we found positive associations between
both MCT4 and CD147 expressions and higher PSA
levels, advanced tumour stage and higher Gleason score
[14,22-25]. However, regarding tumour stage, the differ-
ence in MCT4 expression in the report of Hao and
collaborators [14], appears to be only from pT1 to pT2
and 3 since the levels of the last two appear to be simi-
lar. In our series we do not have pT1 stage cases, which
makes the comparison more difficult. Additionally, we
found associations between MCT1 expression and
higher PSA levels, absence of perineural invasion and
Table 3 Correlations between monocarboxylate transporters (MCTs) and CD147 expressions in prostate tumour
samples and clinico-pathological data
MCT1 MCT2 MCT4 CD147
Variable n ISG %
(n)
p HSG
%(n)
p ISG %
(n)
p HSG
%(n)
p ISG %
(n)
p HSG
%(n)
p ISG %
(n)
p HSG
%(n)
p
Age 0.391 0.073 0.023 0.117 0.247 <
0.001
0.518 <
0.001
> 64 93 19.4
(18)
40.9
(38)
32.6
(30)
48.4
(45)
18.5
(17)
8.6 (8) 17.2
(16)
16.1
(15)
> 64 73 16.4
(12)
53.4
(39)
17.8
(13)
58.9
(43)
24.0
(18)
42.3
(31)
16.2
(12)
54.1
(40)
PSA (ng/ml) 0.414 0.016 0.085 0.250 0.060 <
0.001
0.529 <
0.001
> 11 116 19
(22)
40.5
(47)
29.6
(34)
50.9
(116)
17.2
(20)
11.1
(13)
17.1
(20)
16.2
(19)
> 11 50 16 (8) 60.0
(30)
18.0
(9)
58.0
(50)
29.4
(15)
51.0
(26)
16.0
(8)
72.0
(36)
pT 0.511 0.145 0.528 0.297 0.210 <
0.001
0.396 <
0.001
2 130 18.5
(24)
43.8
(57)
26.4
(34)
51.5
(67)
19.2
(25)
14.5
(19)
16.0
(21)
24.4
(32)
3 36 16.7
(6)
55.6
(20)
25.0
(3)
58.3
(21)
27.0
(10)
54.1
(20)
19.4
(7)
63.9
(23)
Gleason
score
0.251 0.170 0.386 0.857 0.692 0.011 0.850 0.012
< 7 57 15.8
(9)
52.6
(30)
31.6
(18)
54.4
(31)
24.6
(14)
10.5
(6)
15.8
(9)
21.1
(12)
7 100 21.0
(21)
41.0
(41)
22.2
(22)
53.0
(53)
18.8
(19)
28.4
(29)
17.8
(18)
36.6
(36)
> 7 9 0 (0) 66.7
(6)
33.3
(3)
44.4
(4)
22.2
(2)
44.4
(4)
11.1
(1)
66.7
(6)
Perineural
Invasion 0.525 0.036 0.503 0.259 0.397 0.011 0.531 0.021
Absent 52 17.3
(9)
57.7
(30)
26.9
(14)
57.7
(30)
23.1
(12)
11.5
(6)
17.3
(9)
21.2
(11)
Present 114 18.4
(21)
41.2
(47)
25.7
(29)
50.9
(58)
20.0
(23)
28.4
(33)
16.5
(19)
38.3
(44)
Biochemical
Recurrence 0.434 0.047 0.597 0.089 0.200 <
0.001
0.489 <
0.001
Absent 139 18.7
(26)
43.2
(60)
26.1
(36)
50.4
(70)
19.4
(27)
17.1
(24)
16.4
(23)
26.4
(37)
Present 27 14.8
(4)
63.0
(17)
25.9
(7)
66.7
(18)
28.6
(8)
53.6
(15)
18.5
(5)
66.7
(18)
ISG, intermediate score group; HSG, high score group.
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presence of biochemical recurrence, as well as between
both MCT4 and CD147 and presence of perineural
invasion and biochemical recurrence, which to the best
of our knowledge, was not described by others. MCT2
also correlated with lower age at diagnosis, while both
MCT4 and CD147 were associated with higher age at
diagnosis, which significance is not known.
The differences observed between our study and
others, besides the use of different antibodies, might be
also due to the diverse immunohistochemical assess-
ment, while in the present study we considered both
intensity and percentage of immunoreactive cells, other
authors considered only either intensity or extension of
staining [14,22-25]. We believe that evaluating two para-
meters instead of one, decreases subjectivity and will
have higher biological significance. Moreover, our non-
neoplastic tissue was selected from the peripheral zone
of the prostate in which prostate cancer is diagnosed
and this may also have contributed to the differences
observed.
Overall, we found no important clinicopathological
associations with MCT2 but tumours that are highly
positive (HSG) for MCT1, MCT4 or CD147, seem to
exhibit a more aggressive behaviour, especially MCT4
and CD147 which correlated with higher PSA levels,
higher pT stage, higher Gleason score, presence of peri-
neural invasion and biochemical recurrence. However,
to elucidate the significance of these associations, func-
tional studies will be needed.
MCTs and prostate cancer metabolism
At variance with other solid tumours [6,7,9], we did not
find up-regulation of MCT1, MCT4 or CD147 in the
plasma membrane of prostate cancer cells, proteins nor-
mally involved in the hyper glycolytic-acid resistant phe-
notype of cancer cells. On the other hand, there was
upregulation of MCT2 and MCT4 in the cytoplasm of
cancer cells, with a granular appearance. These findings
suggest two hypothesis: either presence of alternative
mechanisms that ensure acid efflux and maintenance of
intracellular pH, or presence of an alternative metabolic
pathway different from glycolysis that predominates in
prostate cancer. Indeed, b-oxidation pathway is sug-
gested to be up-regulated in prostate cancer [32] and
a-methylacyl-CoA racemase (AMACR), an enzyme
involved in branched chain fatty acid b-oxidation, is
already being explored as a diagnostic marker of pros-
tate cancer [33]. Additionally, MCT2, analysed for the
first time in the present work, is involved in short-chain
fatty acid transport and appears overexpressed and with
strong staining in the cytoplasm of prostate tumour
cells, with a granular appearance. These facts point to
this MCT isoform as an important protein in prostate
tumour cells, likely involved in some organelle function.
In fact, the work of McClelland and collaborators pro-
vide evidence for a putative role of MCT2 in hepatocyte
peroxisomal membrane [34].
Conclusion
In the present study, we analysed the expression of
MCT1, MCT2, MCT4, CD147 and gp70, in prostate
cancer, corresponding adjacent non-neoplastic tissue,
normal tissue and PIN lesions, and sought for associa-
tions with the clinico-pathological data of the patients.
Our data provides novel evidence for the involvement of
MCTs in prostate tumours. According to our results, we
believe that MCT2 should be further explored as
tumour marker and MCT4 and CD147 as markers of
poor prognosis in prostate cancer.
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